Amphivena Therapeutics

Amphivena Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company employs 13 people and generates annual revenue exceeding $10,000. Amphivena Therapeutics specializes in developing a novel platform of T cell engagers called Amphivena ReSTORE™. This platform is designed to directly target myeloid derived suppressor cells (MDSC) found in patients with cancer. By neutralizing these cells, Amphivena aims to alleviate the immune suppression often observed in cancer patients, ultimately boosting the effectiveness of cancer therapies. A key differentiator for Amphivena Therapeutics is its focus on controlling cytokine release syndrome (CRS), a potentially dangerous side effect associated with certain cancer treatments. The company's technology is designed to mitigate CRS risk while simultaneously enhancing the anti-tumor immune response. For further information about Amphivena Therapeutics and its innovative treatments, please visit their website at amphivena.com.